The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Pain Score
Timeframe: Baseline (day 0), 45, 60, 75, 90, 105, 135, and 180 days
Number of Participants With a Change in Use of Anti-pain Medication
Timeframe: Baseline through Day 135
Total Number of Adverse Events by Severity
Timeframe: Collected through Day 180